Protagonist Therapeutics, Inc financial data

Symbol
PTGX on Nasdaq
Location
Newark, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 25 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1474% % 13%
Debt-to-equity 8.1% % -34%
Return On Equity -20% % -142%
Return On Assets -18% % -143%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 63,808,716 shares 2.9%
Common Stock, Shares, Outstanding 62,577,897 shares 2.5%
Entity Public Float $2,900,000,000 USD 45%
Common Stock, Value, Issued $1,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 63,573,048 shares 3.3%
Weighted Average Number of Shares Outstanding, Diluted 63,573,048 shares -2.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $159,290,000 USD 15%
General and Administrative Expense $44,853,000 USD 3.2%
Operating Income (Loss) $158,127,000 USD -163%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $129,311,000 USD -146%
Income Tax Expense (Benefit) $838,000 USD -80%
Net Income (Loss) Attributable to Parent $130,149,000 USD -147%
Earnings Per Share, Basic -2.05 USD/shares -146%
Earnings Per Share, Diluted -2.05 USD/shares -148%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $128,390,000 USD 32%
Marketable Securities, Current $438,974,000 USD 36%
Other Assets, Current $10,000 USD -96%
Assets, Current $577,574,000 USD -2.4%
Property, Plant and Equipment, Net $3,860,000 USD 21%
Operating Lease, Right-of-Use Asset $7,829,000 USD -17%
Assets $668,188,000 USD -10%
Accounts Payable, Current $5,339,000 USD 231%
Accrued Liabilities, Current $28,269,000 USD 19%
Liabilities, Current $45,441,000 USD -4.1%
Operating Lease, Liability, Noncurrent $8,040,000 USD -22%
Liabilities $53,481,000 USD -23%
Accumulated Other Comprehensive Income (Loss), Net of Tax $641,000 USD
Retained Earnings (Accumulated Deficit) $470,671,000 USD -38%
Stockholders' Equity Attributable to Parent $614,707,000 USD -9%
Liabilities and Equity $668,188,000 USD -10%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $125,363,000 USD
Net Cash Provided by (Used in) Financing Activities $11,443,000 USD 59%
Net Cash Provided by (Used in) Investing Activities $94,402,000 USD -1655%
Common Stock, Shares Authorized 180,000,000 shares 0%
Common Stock, Shares, Issued 62,577,897 shares 2.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $42,404,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $128,677,000 USD 32%
Deferred Tax Assets, Valuation Allowance $167,141,000 USD 45%
Deferred Tax Assets, Gross $168,846,000 USD 44%
Operating Lease, Liability $10,323,000 USD -5%
Payments to Acquire Property, Plant, and Equipment $545,000 USD 125%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $129,426,000 USD -147%
Lessee, Operating Lease, Liability, to be Paid $11,484,000 USD -9.1%
Property, Plant and Equipment, Gross $12,175,000 USD 19%
Operating Lease, Liability, Current $2,283,000 USD 348%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,884,000 USD 3.5%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,787,000 USD 140%
Operating Lease, Weighted Average Discount Rate, Percent 0.057 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,161,000 USD -34%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,985,000 USD 3.6%
Deferred Tax Assets, Operating Loss Carryforwards $54,046,000 USD 509%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $36,966,000 USD 21%
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,828,000 USD -5.2%
Operating Lease, Payments $696,000 USD 3.3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $239,000 USD 1.3%
Share-based Payment Arrangement, Expense $45,974,000 USD 22%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%